Emerging novel agents for the treatment of mastocytosis
1 vistas
• 07/09/23
0
0
Empotrar
administrator
Suscriptores
Tracy George, MD, ARUP Laboratories, University of Utah, Salt Lake City, UT comments on the movement from broad, cladribine-based regimens to novel, targeted tyrosine kinase inhibitors (TKIs) such as avapritinib, for the treatment of systemic mastocytosis. Dr George also comments on the future development of antibody-based therapies, emphasizing the importance of more selective agents with fewer side effects. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Mostrar más
Comentarios de Facebook
SORT BY-
Top Comentarios
-
Últimos comentarios